2 news items
Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting
ANNX
7 May 24
. These encouraging findings along with the generally well-tolerated safety profile with no incidence of vasculitis hold promise to impact loss of visual acuity
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
ANNX
26 Mar 24
of randomized, double-blind, placebo-controlled, multi-center Phase 3 clinical trial (N=241) designed to evaluate the efficacy, safety, pharmacokinetics
- Prev
- 1
- Next